Abstract
Heat shock protein 90 (HSP90) has been recognized as a crucial target in cancer cells. However, various toxic reactions targeting the ATP binding site of HSP90 may not be the best choice for HSP90 inhibitors. In this paper, an ellagic acid derivative, namely, okicamelliaside (OCS), with antitumor effects was found. To identify potential anti-cancer mechanisms, an OCS photosensitive probe was applied to target fishing and tracing. Chemical proteomics and protein-drug interaction experiments have shown that HSP90 is a key target for OCS, with a strong binding affinity (KD = 6.45 μM). Mutation analysis of the target protein and molecular dynamics simulation revealed that OCS could competitively act on the key Glu-47 site at the N-terminal chaperone pocket of HSP90, where the co-chaperone CDC37 binds to HSP90, affect its stability and reduce the ∆Gbind of HSP90-CDC37. It was demonstrated that OCS destroys the protein–protein interactions of HSP90-CDC37; selectively affects downstream kinase client proteins of HSP90, including CDK4, P-AKT473, and P-ERK1/2; and exerts antitumor effects on A549 cells. Furthermore, tumor xenograft experiments demonstrated high antitumor activity and low toxicity of OCS in the same way. Our findings identified a novel N-terminal chaperone pocket natural inhibitor of HSP90, that is, OCS, which selectively inhibits the formation of the HSP90-CDC37 protein complex, and provided further insight into HSP90 inhibitors for anti-cancer candidate drugs.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Kim YE, Hipp MS, Bracher A, Hayer-Hartl M, Hartl FU. Molecular chaperone functions in protein folding and proteostasis. Annu Rev Biochem. 2013;82:323–55.
Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Targeting HSP90 for cancer therapy. Br J Cancer. 2009;100:1523–9.
Chiosis G, Dickey CA, Johnson JL. A global view of Hsp90 functions. Nat Struct Mol Biol. 2013;20:1–4.
Buc Calderon P, Beck R, Glorieux C. Targeting hsp90 family members: a strategy to improve cancer cell death. Biochem Pharmacol. 2019;164:177–87.
Huang X, Yan X, Zhang Q, Hong P, Zhang W, Liu Y, et al. Direct targeting of HSP90 with daurisoline destabilizes β-catenin to suppress lung cancer tumorigenesis. Cancer Lett. 2020;489:66–78.
Ahmed A, Tait SWG. Targeting immunogenic cell death in cancer. Mol Oncol. 2020;14:2994–3006.
Li J, Xi W, Li X, Sun H, Li Y. Advances in inhibition of protein-protein interactions targeting hypoxia-inducible factor-1 for cancer therapy. Bioorg Med Chem. 2019;27:1145–58.
Kaneda A, Seike T, Danjo T, Nakajima T, Otsubo N, Yamaguchi D, et al. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma. Am J Cancer Res. 2020;10:4399–415.
Wang J, Wang L, Zhang S, Fan J, Yang H, Li Q, et al. Novel eIF4E/eIF4G protein-protein interaction inhibitors DDH-1 exhibits anti-cancer activity in vivo and in vitro. Int J Biol Macromol. 2020;160:496–505.
Bhat R, Tummalapalli SR, Rotella DP. Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors. J Med Chem. 2014;57:8718–28.
Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 2013;14:e358–69.
Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 2012;1823:742–55.
Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, et al. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res. 2011;17:6831–9.
Calderwood SK. Molecular cochaperones: tumor growth and cancer treatment. Science. 2013;2013:217513.
Retzlaff M, Hagn F, Mitschke L, Hessling M, Gugel F, Kessler H, et al. Asymmetric activation of the hsp90 dimer by its cochaperone aha1. Mol Cell. 2010;37:344–54.
Pearl LH. Hsp90 and Cdc37—a chaperone cancer conspiracy. Curr Opin Genet Dev. 2005;15:55–61.
Stepanova L, Yang G, DeMayo F, Wheeler TM, Finegold M, Thompson TC, et al. Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene. 2000;19:2186–93.
Wang L, Zhang L, Li L, Jiang J, Zheng Z, Shang J, et al. Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer. Sci Adv. 2019;5:eaax2277.
Smith JR, Workman P. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning. Cell Cycle. 2009;8:362–72.
Zhang W, Gao J, Cheng C, Zhang M, Liu W, Ma X, et al. Cinnamaldehyde enhances antimelanoma activity through covalently binding ENO1 and exhibits a promoting effect with dacarbazine. Cancers. 2020;12:311.
Gao J, He X, Ma Y, Zhao X, Hou X, Hao E, et al. Chlorogenic acid targeting of the AKT PH domain activates AKT/GSK3β/FOXO1 signaling and improves glucose metabolism. Nutrients 2018;10:1366.
Cheng C, Shen F, Ding G, Liu A, Chu S, Ma Y, et al. Lepidiline a improves the balance of endogenous sex hormones and increases fecundity by targeting HSD17B1. Mol Nutr Food Res. 2020;64:e1900706.
Salomon-Ferrer R, Götz AW, Poole D, Le Grand S, Walker RC. Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh ewald. J Chem Theory Comput. 2013;9:3878–88.
Sousa da Silva AW, Vranken WF. ACPYPE—antechamber python parser interface. BMC Res Notes. 2012;5:367.
Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2005;26:114.
Wang J, Wang W, Kollman PA, Case DA. Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model. 2006;25:247–60.
Zhang Y, Wang Z, Ma X, Yang S, Hu X, Tao J, et al. Glycyrrhetinic acid binds to the conserved P-loop region and interferes with the interaction of RAS-effector proteins. Acta Pharm Sin B. 2019;9:294–303.
Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma. Nat Med. 2009;15:750–6.
Kelly SM, Jess TJ, Price NC. How to study proteins by circular dichroism. Biochim Biophys Acta. 2005;1751:119–39.
Manvar D, Mishra M, Kumar S, Pandey VN. Identification and evaluation of anti hepatitis C virus phytochemicals from Eclipta alba. J Ethnopharmacol. 2012;144:545–54.
Schweiger R, Soll J, Jung K, Heermann R, Schwenkert S. Quantification of interaction strengths between chaperones and tetratricopeptide repeat domain-containing membrane proteins. J Biol Chem. 2013;288:30614–25.
Chen PH, Unger V, He X. Structure of full-length human PDGFRβ bound to its activating ligand PDGF-B as determined by negative-stain electron microscopy. J Mol Biol. 2015;427:3921–34.
Wei Y, Yang Q, Zhang Y, Zhao T, Liu X, Zhong J, et al. Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells. Oncotarget. 2017;8:15230–41.
Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D. Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J Biol Chem. 2009;284:35381–9.
Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res. 2009;15:9–14.
Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell. 2003;3:213–7.
Krishna P, Gloor G. The Hsp90 family of proteins in Arabidopsis thaliana. Cell Stress Chaperones. 2001;6:238–46.
Prodromou C, Roe SM, O’Brien R, Ladbury JE, Piper PW, Pearl LH. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell. 1997;90:65–75.
Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA. 1994;91:8324–8.
Cervantes-Gomez F, Nimmanapalli R, Gandhi V. Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and actinomycin D. Cancer Res. 2009;69:3947–54.
Taldone T, Chiosis G. Purine-scaffold Hsp90 inhibitors. Curr Top Med Chem. 2009;9:1436–46.
Jhaveri K, Ochiana SO, Dunphy MP, Gerecitano JF, Corben AD, Peter RI, et al. Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opin Investig Drugs. 2014;23:611–28.
Donnelly AC, Mays JR, Burlison JA, Nelson JT, Vielhauer G, Holzbeierlein J, et al. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. J Org Chem. 2008;73:8901–20.
Dai J, Chen A, Zhu M, Qi X, Tang W, Liu M, et al. Penicisulfuranol A, a novel C-terminal inhibitor disrupting molecular chaperone function of Hsp90 independent of ATP binding domain. Biochem Pharmacol. 2019;163:404–15.
Wang L, Li L, Zhou ZH, Jiang ZY, You QD, Xu XL. Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction. Eur J Med Chem. 2017;136:63–73.
Huang W, Ye M, Zhang LR, Wu QD, Zhang M, Xu JH, et al. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation. Mol Cancer. 2014;13:150.
Grover A, Shandilya A, Agrawal V, Pratik P, Bhasme D, Bisaria VS, et al. Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A. BMC Bioinform. 2011;12:S30.
Zhao M, Ma J, Zhu HY, Zhang XH, Du ZY, Xu YJ, et al. Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. Mol Cancer. 2011;10:104.
Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther. 2008;7:162–70.
Wang L, Jiang J, Zhang L, Zhang Q, Zhou J, Li L, et al. Discovery and optimization of small molecules targeting the protein-protein interaction of heat shock protein 90 (Hsp90) and cell division cycle 37 as orally active inhibitors for the treatment of colorectal cancer. J Med Chem. 2020;63:1281–97.
Luo M, Meng Z, Moroishi T, Lin KC, Shen G, Mo F, et al. Heat stress activates YAP/TAZ to induce the heat shock transcriptome. Nat Cell Biol. 2020;22:1447–59.
Acknowledgements
This study was supported by Guangxi Innovation-driven Development 20 Special Foundation Project (Guike No. AA18118049). We would like to thank Nature Research Editing (https://authorservices.springernature.com/) for English language editing.
Author information
Authors and Affiliations
Contributions
Conceptualization, GB and YYH; Data curation and formal analysis, CJC; Funding acquisition, XTH; EWH and GB; Investigation, CJC and YYH; Methodology, CJC; KXL; MZ; LLY; FKS and WBW; Supervision, GB; Validation, CJC and YYH; Writing-original draft, CJC; Writing-review & editing, GB and YYH.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Cheng, Cj., Liu, Kx., Zhang, M. et al. Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity. Acta Pharmacol Sin 43, 1046–1058 (2022). https://doi.org/10.1038/s41401-021-00737-x
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41401-021-00737-x
Keywords
This article is cited by
-
Advances in the structures, mechanisms and targeting of molecular chaperones
Signal Transduction and Targeted Therapy (2025)
-
Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies
Journal of Hematology & Oncology (2024)
-
HSP90 mediates the connection of multiple programmed cell death in diseases
Cell Death & Disease (2022)
